Edesa Biotech

Edesa Biotech announces a guaranteed public offering expected to raise approximately $25.0 million gross proceeds through the sale of common stock, associated warrants and pre-funded warrants. The combined offering is priced at $5.50 per common share plus warrant; pre-funded warrants are priced at $5.4999. The warrants have an exercise price of $7.50 and are immediately exercisable. There is a 30-day overallotment option for the underwriting banks, the closing is expected around August 21, 2026, and the proceeds are to be used for general corporate purposes as well as research & development and manufacturing. » Mere på de.investing.com

Edesa Biotech has announced a guaranteed public offering of common shares or pre-funded warrants, together with accompanying warrants, after which the stock fell 15.2% in after-hours trading. The consortium is to be granted a 30-day option to purchase additional securities of up to 15% of the offering. Guggenheim Securities is sole bookrunner; the transaction is subject to market conditions and is expected to provide net proceeds for general corporate purposes, including working capital, research and manufacturing. » Mere på de.investing.com

Edesa Biotech announced a public, syndicated offering of common stock or pre-funded warrants and accompanying warrants, with a syndicate option for up to 15% of the offering size. Guggenheim Securities is acting as sole book-running manager. Net proceeds are intended for general corporate purposes, including working capital and research, development and production. The offering is being made pursuant to an S-3 shelf registration and is subject to market conditions; final closing and terms are not guaranteed. » Mere på de.investing.com